When the FDA approved Casgevy as the first therapy using CRISPR gene-editing technology in 2023, sickle cell anemia patients and their caregivers were astonished, hopeful, and concerned. It had been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback